Conference Coverage

RAPID ART program yields clinical benefits in San Francisco


 

REPORTING FROM CROI


He acknowledged that the analysis did not address the important question of durability of virologic suppression.

The San Francisco Getting to Zero Consortium is sponsored by Gilead, Janssen, Bristol-Myers Squibb, the City of San Francisco, and by Will Hagerty. Dr. Bacon reported no conflicts of interest to disclose.

SOURCE: Buchbinder SP et al. CROI 2018, Abstract 87.

Pages

Recommended Reading

One-month TB-prevention regimen effective in HIV+ individuals
MDedge Infectious Disease
Hair tracks HIV antiretroviral adherence
MDedge Infectious Disease
Follow our continuing CROI coverage
MDedge Infectious Disease
FDA approves new treatment for multidrug-resistant HIV
MDedge Infectious Disease
HIV diagnosis at home and same-day ART start tied to better outcomes
MDedge Infectious Disease
Raltegravir not associated with IRIS in African trial
MDedge Infectious Disease
‘Clean and sober’ ex-prisoners have better HIV suppression
MDedge Infectious Disease
Looking to increase PrEP uptake
MDedge Infectious Disease
Hospital urine screening reduces TB deaths in HIV+ adults
MDedge Infectious Disease
Dolutegravir-based regimen effective in HIV/TB coinfected
MDedge Infectious Disease